๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Quality of life in obsessive-compulsive disorder: an evaluation of impairment and a preliminary analysis of the ameliorating effects of treatment

โœ Scribed by Melissa M. Norberg; John E. Calamari; Robyn J. Cohen; Bradley C. Riemann


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
150 KB
Volume
25
Category
Article
ISSN
1091-4269

No coin nor oath required. For personal study only.

โœฆ Synopsis


Despite the substantial impairments in life functioning associated with obsessive-compulsive disorder (OCD), treatment outcome evaluations have focused almost exclusively on symptom reduction, a focus that may be too narrow to determine whether clinically significant change has occurred. Quality of life (QOL) impairment was evaluated in a clinical OCD sample (N 5 188) using a multidimensional life satisfaction measure. Relationships between treatment response and QOL change also were evaluated with a subsample of participants (n 5 120). Congruent with previous studies of OCD, substantial pretreatment QOL impairment was found across all life domains. Distinct treatment change subgroups were identified: a group reporting strong symptom reduction and very good QOL gains, a second group with significant symptom reduction but less robust QOL improvements, and a third group with limited symptom gains and QOL decreases. Implications for understanding OCD-related impairment and the clinical significance of treatment outcomes are discussed. Depression and Anxiety 25:248-259, 2008.


๐Ÿ“œ SIMILAR VOLUMES


Factor analysis of the Yaleโ€“Brown Obsess
โœ Bernadette Cullen; Clayton H. Brown; Mark A. Riddle; Marco Grados; O. Joseph Bie ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 145 KB ๐Ÿ‘ 1 views

Our objective in this study was to determine whether symptoms of obsessive-compulsive disorder (OCD) cluster into groups that can usefully subclassify OCD. Psychiatrists or psychologists interviewed 221 subjects using the Lifetime Anxiety Version of the Schedule for Affective Disorders and Schizophr